405 related articles for article (PubMed ID: 27565924)
1. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung.
Semper H; Muehlberg F; Schulz-Menger J; Allewelt M; Grohé C
Lung Cancer; 2016 Sep; 99():117-9. PubMed ID: 27565924
[TBL] [Abstract][Full Text] [Related]
2. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
[TBL] [Abstract][Full Text] [Related]
3. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.
Gounant V; Brosseau S; Naltet C; Opsomer MA; Antoine M; Danel C; Khalil A; Cadranel J; Zalcman G
Lung Cancer; 2016 Sep; 99():162-5. PubMed ID: 27565934
[TBL] [Abstract][Full Text] [Related]
5. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
Fujimoto D; Morimoto T; Ito J; Sato Y; Ito M; Teraoka S; Otsuka K; Nagata K; Nakagawa A; Tomii K
Lung Cancer; 2017 Sep; 111():1-5. PubMed ID: 28838377
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment.
Kimura H; Sone T; Murata A; Koba H; Tambo Y; Hara J; Abo M; Kasahara K
Lung Cancer; 2017 Jun; 108():7-8. PubMed ID: 28625651
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
[TBL] [Abstract][Full Text] [Related]
8. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report.
Ikeuchi K; Okuma Y; Tabata T
Lung Cancer; 2016 Sep; 99():148-50. PubMed ID: 27565931
[TBL] [Abstract][Full Text] [Related]
9. Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.
Gokozan HN; Friedman JD; Schmaier AH; Downes KA; Farah LA; Reeves HM
Clin Lung Cancer; 2019 Sep; 20(5):e560-e563. PubMed ID: 31311716
[No Abstract] [Full Text] [Related]
10. Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
Gion M; Remon J; Caramella C; Soria JC; Besse B
Lung Cancer; 2017 Jun; 108():72-74. PubMed ID: 28625652
[TBL] [Abstract][Full Text] [Related]
11. Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer.
Dasanu CA; Lippman SM; Plaxe SC
J Oncol Pharm Pract; 2017 Dec; 23(8):638-640. PubMed ID: 27824586
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature.
Matsuo K; Ishiguro T; Najama T; Shimizu Y; Kobayashi Y; Mutou M
Intern Med; 2019 Aug; 58(16):2367-2372. PubMed ID: 31118387
[TBL] [Abstract][Full Text] [Related]
13. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab.
Tabchi S; Weng X; Blais N
Lung Cancer; 2016 Sep; 99():123-6. PubMed ID: 27565926
[TBL] [Abstract][Full Text] [Related]
14. Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.
Raskin J; Masrori P; Cant A; Snoeckx A; Hiddinga B; Kohl S; Janssens A; Cras P; Van Meerbeeck JP
Lung Cancer; 2017 Jul; 109():74-77. PubMed ID: 28577954
[TBL] [Abstract][Full Text] [Related]
15. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.
Dudnik E; Yust-Katz S; Nechushtan H; Goldstein DA; Zer A; Flex D; Siegal T; Peled N
Lung Cancer; 2016 Aug; 98():114-117. PubMed ID: 27393516
[TBL] [Abstract][Full Text] [Related]
16. Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab.
Tadokoro T; Keshino E; Makiyama A; Sasaguri T; Ohshima K; Katano H; Mohri M
Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27650418
[No Abstract] [Full Text] [Related]
17. Rapid and partial remission of primary lesion but complicated by secondary fibrosis after treatment with nivolumab in a lung squamous carcinoma.
Ding L; Zhu Y; Chen C
Ther Adv Respir Dis; 2017 Feb; 11(2):129-132. PubMed ID: 27903791
[No Abstract] [Full Text] [Related]
18. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression.
Takeshita M; Anai S; Mishima S; Inoue K
Ann Oncol; 2017 Jan; 28(1):186-189. PubMed ID: 28043982
[No Abstract] [Full Text] [Related]
19. Fatal association of fulminant myocarditis and rhabdomyolysis after immune checkpoint blockade.
Tomoaia R; Beyer RȘ; Pop D; Minciună IA; Dădârlat-Pop A
Eur J Cancer; 2020 Jun; 132():224-227. PubMed ID: 32336614
[No Abstract] [Full Text] [Related]
20. [Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC): a case report].
Tan KX; Li CY; Zhang JY; Cui HJ; Shen W; Zhang X; Sun CY; Jiang XJ; Zheng SY; Li J; Xue CX
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1047-1048. PubMed ID: 33342162
[No Abstract] [Full Text] [Related]
[Next] [New Search]